What is the risk of venous thromboembolism (VTE) in the 12 weeks following early pregnancy loss in pregnancies conceived by IVF?
Introduction
Venous thromboembolism (VTE) is a concern in relation to IVF (Hansen et al., 2012 and Rova et al., 2012; Henriksson et al., 2013) . VTE is potentially fatal, and identifying women at risk is pivotal (Bates et al., 2016) . The IVF procedure itself is not a risk factor for VTE in unsuccessful IVF cycles (Hansen et al., 2012) . However, when pregnancy is achieved by the use of IVF, there is an excess VTE risk during the first trimester compared to the general population of pregnancies (Rova et al., 2012; Henriksson et al., 2013; Hansen et al., 2014) . This increased risk is mainly driven by the subgroup of women developing ovarian hyperstimulation syndrome (OHSS) (Rova et al., 2012; Hansen et al., 2014; Sennström et al., 2017) . Data on the postpartum VTE risk following IVF pregnancies have been conflicting (Jacobsen et al., 2008; Rova et al., 2012; Henriksson et al., 2013; Hansen et al., 2014) . According to international guidelines, women undergoing IVF and suffering OHSS should receive prophylactic treatment with low molecular weight heparin during the first trimester, whereas all other IVF patients should be VTE riskstratified according to the usual antenatal risk-evaluation (Bates et al., 2016; Sennström et al., 2017; Green-top Guideline No. 37a) .
It remains unclear whether the excess VTE risk demonstrated in complete IVF pregnancies also is present in IVF pregnancies terminated by early pregnancy loss. This leaves fertility doctors with the question as to whether this subgroup of women are also at increased risk of VTE following these events, potentially needing subsequent prophylactic anticoagulant therapy. We aimed to fill this knowledge gap. By the use of nationwide Danish registry data, we here report the VTE risk during the 12 weeks following early pregnancy loss in IVF pregnancies.
Materials and Methods

Setting
Individuals born in or immigrating to Denmark receive a unique Civil Personal Registration number, enabling valid linkage among Danish registries at the individual level (Schmidt et al., 2014) . The present study was based on nationwide register data covering all IVF treated women in Denmark, in the period from 1995 to 2005 (described in detail in Hansen et al., 2012 Hansen et al., , 2014 .
We obtained data from the Danish IVF Register (Andersen et al., 1999 ) and the Danish National Patient Registry (Schmidt et al., 2014) . Since 1994, there has been mandatory reporting of all IVF treatments in Denmark for both private and public IVF clinics to the Danish IVF Register (Andersen et al., 1999) . The IVF Register also includes information from the Danish National Patient Registry on pregnancy outcomes. We obtained cycle-specific information on the type and date of treatment, and the occurrence of pregnancy, early pregnancy loss, abortions and deliveries.
The Danish National Patient Registry contains data on all admissions and discharges from Danish hospitals since 1977 and from emergency room and outpatient clinic visits since 1995 (Lynge et al., 2011; Schmidt et al., 2014) .
Each hospital inpatient discharge and hospital outpatient visit is recorded in the registry with one primary diagnosis and an optional number of secondary diagnoses classified according to the International Classification of Diseases, the 10th revision (ICD-10) from 1994 and thereafter (Lynge et al., 2011; Schmidt et al., 2014) .
Study population
We identified and included all women who conceived by the use of IVF at public or private fertility clinics in Denmark from 1995 to 2005. Women who underwent frozen embryo replacement or oocyte donation were not included. Women with a history of VTE, arterial thrombosis or malignancy diagnosis before the index pregnancy were excluded, since we aimed to study incident cases of VTE. Figure 1 reports a flow diagram of inclusions and exclusions for the final cohort included in the statistical analyses.
Pregnancy loss
We defined early pregnancy loss in IVF pregnancies as the subgroup of pregnancies terminated due to implantation failure, missed abortion, or spontaneous or induced abortion before 10 completed gestational weeks ( Kolte et al., 2015) . For implantation failure and missed abortion, the date of loss is poorly defined, so for these women we chose to include VTE events within 20 weeks after embryo transfer. We defined late pregnancy loss in IVF pregnancies as the subgroup of pregnancies terminated due to missed abortion, or spontaneous or induced abortion from 10 completed gestational weeks until 22 completed gestational weeks.
Venous thromboembolism
The main outcome was incident VTE recorded in the Danish National Patient Registry following IVF pregnancies terminated by either delivery (complete IVF pregnancies) or early IVF pregnancy loss or abortion. We used the following ICD-10 codes to identify VTE episodes: I26, I80.1-I82.9, O08.2, O08.7, O22.3, O22.5, O87.1, O87.3 and O88.2.
Comorbidity
For all women included in the study, we obtained information from the Danish National Patient Registry on pre-existing disease before date of embryo transfer, including polycystic ovary syndrome (PCOS), diabetes and OHSS in the index pregnancy. Information on smoking and maternal BMI was available only for complete pregnancies terminated by a delivery and therefore not included in the present paper.
Statistical analyses
We followed women carrying IVF pregnancies from the date of delivery or pregnancy loss until 12 weeks after that date. We computed the absolute number of VTEs during follow-up and calculated the cumulative incidence proportions for VTE within 12 weeks, presented as the number of VTEs occurring per 10 000 pregnancies with 95% CI. For comparison of the absolute VTE risk within 12 weeks following complete IVF pregnancies and early pregnancy loss, we computed a risk ratio with 95% CI and used Fisher's exact significance test. The statistical software Stata, version 13, (StataCorp LP. 2013, College Station, TX, USA) was used for the statistical analysis.
Ethical approval
According to Danish law, ethics approval is not needed for studies that are entirely registry-based.
Results
We identified and included all 24 931 IVF treatments leading to pregnancy among 19 260 women (Fig. 1 ). Of these, 7567 were terminated as early pregnancy loss and 663 were late pregnancy loss gestational age ≥10 weeks (Table I) . Table I presents the distribution of maternal age at embryo transfer, pre-existing PCOS and diabetes, separately for pregnancies terminated by early or late loss, and for the complete pregnancies terminated by a delivery.
During the 12 weeks of follow-up, one case of VTE occurred in the group of early pregnancy loss (Table II) . The VTE, a deep vein thrombosis, occurred 33 days after embryo transfer in an IVF pregnancy terminated by missed abortion and with no OHSS registered for the woman. There were no VTEs registered in the late abortion group. Overall, 13 VTE cases occurred in the group of complete IVF pregnancies, in all 13 cases without OHSS registered. The VTE risk per 10 000 pregnancies was 1.3 [0.03-7.4] for IVF pregnancies with early loss and 7.8 [4.1-13.3] for complete pregnancies; the corresponding risk ratio was 0.17 [0.02-1.3] for VTE occurring after early IVF pregnancy loss compared to the complete IVF pregnancies (Table II) .
Discussion
Principal findings
In this nationwide study, we found that women suffering early pregnancy loss in IVF pregnancies do not seem to have a subsequently increased risk of VTE. The VTE risk in early IVF pregnancy loss was 1.3 per 10 000 pregnancies [0.03-7.4]. For comparison, the first trimester VTE risk in the population of all Danish pregnancies has been reported much higher, at 5.7 per 10 000 pregnancies (Virkus et al., 2011) .
The early IVF pregnancy loss occurs during first trimester, during which period there is reported a substantially increased VTE risk in IVF pregnancies leading to delivery (Rova et al., 2012; Henriksson et al., 2013; Hansen et al., 2014; Sennström et al., 2017 Women with a history of venous thromboembolism (VTE), arterial thrombosis or malignancy diagnosis before the index pregnancy not included. Early IVF pregnancy loss: IVF pregnancies terminated due to implantation failure, missed abortion or abortion before 10 completed gestational weeks (Kolte et al., 2015) . Late pregnancy loss in IVF pregnancies: IVF pregnancies terminated due to missed abortion, or abortion ≥10 completed gestational weeks <22 completed gestational weeks a At date of embryo transfer. prophylactic anticoagulant therapy. However, the present results suggest that there is no need for prophylactic anticoagulant therapy in women suffering early IVF pregnancy loss without other risk factors. The low VTE risk following early pregnancy loss in IVF pregnancies is probably due to a poor placentation with minor hemostatic changes compared to that normally observed during pregnancy (Hansen et al., 2011) . Furthermore, the excess first trimester VTE risk observed in complete IVF pregnancies is driven mainly by OHSS (Hansen et al., 2014; Bates et al., 2016; Sennström et al., 2017) .
Strengths and weaknesses of the study
Our registry-based nationwide study on prospectively collected data with complete follow-up likely eliminated selection bias. The mandatory reporting from both public and private fertility clinics ensured complete data on all IVF treatments performed in Denmark (Andersen et al., 1999) . Danish health care data are collected close to the event in question. This does not eliminate the risk of misclassification, but it reduces the risk of differential misclassification. Specifically, the positive predictive value of incident and recurrent ICD-10 VTE diagnoses is high in the Danish National Patient Registry (70-100%) (Larsen et al., 2005; Sundbøll et al., 2016) . We included both inpatient and outpatient VTE hospital diagnoses, but we cannot rule out the occurrence of VTE cases not diagnosed at hospital and hence not registered in the National Patient Registry.
Despite the use of nationwide data over a period of 11 years, only a few VTE events were available for the statistical analyses rendering our estimates rather imprecise. Thus, the statistical imprecision of the risk estimate was a direct consequence of the rarity of events, which is the main finding of the present study. Even if the upper limit of the 95% CI (7.4 VTE events per 10 000 pregnancies) reflects the true VTE risk following early IVF pregnancy loss, it is a low VTE risk and similar to the reported VTE risk in Danish pregnancies of 5.7 per 10 000 pregnancies (Virkus et al., 2011) .
The relative VTE risk in IVF pregnancies terminated by early loss versus IVF pregnancies leading to delivery was not statistically significant. Nevertheless, the risk ratio provides clinically significant information in addition to the absolute risk estimates showing that a VTE following early IVF pregnancy loss is a rare event.
We report the absolute risks of VTE in a subgroup of the entire IVF pregnancy cohort, namely the early IVF pregnancy loss with comparison to the IVF pregnancies leading to delivery. Confounding is not a problem in the present paper, since we report absolute risk estimates without investigating the causes of the VTE event. We found similar distributions of OHSS in index pregnancy, PCOS and preexisting diabetes across the groups. Women suffering late pregnancy loss were older than women in the early loss and complete pregnancy groups. It has previously been reported that maternal age does not seem to affect VTE risk in complete IVF pregnancies (Henriksson et al., 2013; Hansen et al., 2014) , and that there is an almost identical distribution of maternal BMI and smoking habits in complete IVF pregnancies and the general population of pregnancies (Romundstad et al., 2008; Henriksson et al., 2013) .
We did not have information on the use of prophylactic low molecular weight heparin. Access to such might have helped to explain our findings, but would not have changed our conclusions of a low absolute VTE risk following early pregnancy loss in IVF pregnancies.
Conclusion
In conclusion, we found evidence for a low VTE risk in the 12 weeks following early pregnancy loss in IVF pregnancies. Thus, these data do not indicate a benefit of prophylactic anticoagulant therapy in women suffering early IVF pregnancy loss without other risk factors.
Questions, which remain to be answered in future research
Future observational studies may preferably be based on even larger datasets for improved statistical precision on the VTE risk after early IVF pregnancy loss.
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